Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease.

Cancer biology & therapy - 1 Jan 2018

Yuan Gang, Liu Qiuli, Tong Dali, Liu Gaolei, Yi Yuting, Zhang Jun, Zhang Yao, Wang Lin-Ang, Wang Luofu, Chen Rongrong, Guan Yanfang, Yi Xin, Lan Weihua, Jiang Jun

Abstract excerpt

Von Hippel-Landau (VHL) disease is characterized by malignant and benign tumors in multiple organs. Sunitinib, a tyrosine kinase inhibitor, has been clinically available for treating sporadic patients with recurrent or unresectable and metastatic clear renal cell carcinomas (cRCCs) and metastatic lesions of the lung, but its effect on VHL disease-associated tumors remains poorly understood. This retrospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Renal Cell

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Magnetic Resonance Imaging

Share to Protein Kinase Inhibitors

Share to Sunitinib

Share to Tomography, X-Ray Computed

Share to Treatment Outcome

Share to von Hippel-Lindau Disease

Source

Open in PubMed Open full text

Identifiers

PMID: 29947576
DOI: 10.1080/15384047.2018.1470732
PMCID: PMC6154838

Genes

VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A retrospective case study of sunitinib treatment in three patients with Von Hippel-Lindau disease.PMID 29947576Read ↗

Von Hippel-Lindau Disease Presenting with Renal Cell Carcinoma and Multiple Organ Involvement: A Case ReportSemantic proximity Read ↗

Clinical, surgical, pathological and follow-up features of kidney cancer patients with Von Hippel-Lindau syndrome: novel insights from a large consortium.Semantic proximity Read ↗

Sinonasal renal cell-like adenocarcinoma arising in von Hippel Lindau (VHL) syndrome.Semantic proximity Read ↗

A Case of von Hippel-Lindau Disease with Colorectal Adenocarcinoma, Renal Cell Carcinoma and Hemangioblastomas.Semantic proximity Read ↗

MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinomaSemantic proximity Read ↗

von Hippel-Lindau Disease: Review of Genetics and Imaging.Semantic proximity Read ↗

Juvenile renal cell carcinoma as first manifestation of von Hippel-Lindau disease.Semantic proximity Read ↗

Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma.Semantic proximity Read ↗

Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.Semantic proximity Read ↗

Complete remission with sunitinib in a poor-risk patient with metastatic renal cell carcinoma: the fine balance between toxicity and efficacy.Semantic proximity Read ↗

Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?Semantic proximity Read ↗

Multifocal renal oncocytoma in a patient with Von Hippel-Lindau mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.